Tirzepatide for weight loss in stimulant use disorder
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether a weekly injection called tirzepatide (a diabetes and weight-loss medication) can help people with obesity and stimulant use disorder reduce stimulant use and lose weight. It aims to see if treating both conditions together improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with moderate to severe methamphetamine, cocaine, or prescription stimulant use disorder.
- You have used stimulants on at least 18 days in the past 30 days.
- Your body mass index (BMI) is 30 or higher, or 27 or higher with a weight-related condition like high blood pressure, diabetes, or sleep apnea.
- You are not currently using any GLP-1 medication, other weight-loss drugs, or insulin.
- You do not have severe kidney disease, uncontrolled diabetes, or a personal or family history of medullary thyroid cancer.
- You can undergo an MRI (no pacemaker or metal in body, and not claustrophobic).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
This study tests a medication called tirzepatide (a once-weekly injection) to help teenagers with obesity and related health conditions lose weight. It aims to see if the drug is safe and effective for this age group.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This trial tests the safety and effectiveness of tirzepatide, a once-weekly injection, for weight loss in people with obesity. It might be an option if you have a BMI of 27 or higher with weight-related health problems, or a BMI of 35 or higher, and live in or near Asunción, Paraguay.
This trial tests a once-weekly injection (tirzepatide) versus a placebo to help people who are obese or overweight with related health conditions lose weight. You may qualify if you have tried to lose weight through diet before, but have not been successful.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.